ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
Public ClinicalTrials.gov record NCT04856865. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Harmony Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
Study identification
- NCT ID
- NCT04856865
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 73 participants
Conditions and interventions
Conditions
Interventions
- Low dose ADP101 Biological
- High dose ADP101 Biological
- Pooled Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 4 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 20, 2021 (Actual)
- Primary completion
- Nov 22, 2022 (Actual)
- Completion
- Dec 13, 2022 (Actual)
- Last update posted
- May 16, 2024
2021 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Mission Viejo | California | 92691 | — |
| Study Site | Rolling Hills Estates | California | 90274 | — |
| Study Site | San Diego | California | 92123 | — |
| Study Site | Denver | Colorado | 80230 | — |
| Study Site | Tampa | Florida | 33620 | — |
| Study Site | Atlanta | Georgia | 30329 | — |
| Study Site | Marietta | Georgia | 30060 | — |
| Study Site | Normal | Illinois | 61761 | — |
| Study Site | Ann Arbor | Michigan | 48108 | — |
| Study Site | Chapel Hill | North Carolina | 27599 | — |
| Study Site | Cincinnati | Ohio | 45229 | — |
| Study Site | Happy Valley | Oregon | 97086 | — |
| Study Site | Philadelphia | Pennsylvania | 19104 | — |
| Study Site | Charleston | South Carolina | 29420 | — |
| Study Site | Seattle | Washington | 98115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04856865, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04856865 live on ClinicalTrials.gov.